ConjuChem, Inc. is a Montreal-based biotechnology company focused on discovering and developing new drugs based on its novel technology platform called Drug Affinity Construct (DAC™). When applied to a compound, DAC™ can create a new drug with similar therapeutic activity but a significantly longer duration of activity in the body. One of the greatest opportunities for ConjuChem's DAC™ technology is its ability to harness the profound therapeutic potential of peptides, which are hindered by a variety of limitations. In particular, peptides have short durations of in vivo activity caused by their rapid degradation and elimination from the blood stream. This not only decreases their efficacy, but can also hold back their commercialization potential. ConjuChem's DAC™ technology, which is administered through subcutaneous (SC) injection but can also be administered intravenously (IV) or intramuscularly (IM), is targeted towards novel therapeutics or new chemical entities (NCEs) in the areas of diabetes, growth hormone deficiencies, human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), and congestive heart failure.
* The Corporate Snapshot was last updated on March 17, 2004.
Click to View